Topiramate in Lennox–Gastaut Syndrome: Open‐Label Treatment of Patients Completing a Randomized Controlled Trial

Authors:
  • TGTopiramate YL Study Group
    Topiramate YL Study Group

Abstract
Summary: Purpose: The response to topiramate (TPM) as long‐term adjunctive therapy was evaluated in patients with Lennox‐Gastaut syndrome (LGS) in a long‐term, open‐label extension to a double‐blind, placebo‐controlled trial. Methods: In 97 patients with LGS (mean age, 11 years), dosages of TPM and concomitant antiepileptic drugs (AEDs) were adjusted to optimal clinical response (mean TPM dosage, 10 mg/kg/day). Results: For those patients who had completed 6 months of TPM therapy, drop attacks were reduced ges;50% in 55% of patients; 15% of patients had no drop attacks for ges;6 months at the last visit. After treatment up to 3+ years, 71% of patients who started open‐label TPM were continuing therapy at the last visit. Conclusions: During long‐term therapy, TPM is effective and well tolerated in controlling the treatment‐resistant drop attacks and seizures associated with LGS.

This publication has 26 references indexed in Scilit: